Antisense oligonucleotides targeting angiotensinogen: Insights from animal studies

Chia Hua Wu; Ya Wang; Murong Ma; Adam E. Mullick; Rosanne M. Crooke; Mark J. Graham; Alan Daugherty; Hong S. Lu

doi:10.1042/BSR20180201

Antisense oligonucleotides targeting angiotensinogen: Insights from animal studies

Chia Hua Wu, Ya Wang, Murong Ma, Adam E. Mullick, Rosanne M. Crooke, Mark J. Graham, Alan Daugherty, Hong S. Lu

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.

Original language	English
Article number	BSR20180201
Journal	Bioscience Reports
Volume	39
Issue number	1
DOIs	https://doi.org/10.1042/BSR20180201
State	Published - Jan 11 2019

Bibliographical note

Funding Information:
The authors’ research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health [grant numbers R01HL139748, R01HL133723] and the National Natural Science Foundation of China [grant numbers 81320108003, 31371498 (to Y.W.)]; Employees of Ionis Pharmaceuticals, Inc. [to A.E.M. and R.M.C.]; M.J.G. was an employee of Ionis Pharmaceuticals, Inc. The content in this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2019 The Author(s).

ASJC Scopus subject areas

Biophysics
Biochemistry
Molecular Biology
Cell Biology

Access to Document

10.1042/BSR20180201

Cite this

@article{38e8c15650744fdfb055176fb598dfdd,

title = "Antisense oligonucleotides targeting angiotensinogen: Insights from animal studies",

abstract = "Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.",

author = "Wu, {Chia Hua} and Ya Wang and Murong Ma and Mullick, {Adam E.} and Crooke, {Rosanne M.} and Graham, {Mark J.} and Alan Daugherty and Lu, {Hong S.}",

note = "Funding Information: The authors{\textquoteright} research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health [grant numbers R01HL139748, R01HL133723] and the National Natural Science Foundation of China [grant numbers 81320108003, 31371498 (to Y.W.)]; Employees of Ionis Pharmaceuticals, Inc. [to A.E.M. and R.M.C.]; M.J.G. was an employee of Ionis Pharmaceuticals, Inc. The content in this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = jan,

day = "11",

doi = "10.1042/BSR20180201",

language = "English",

volume = "39",

number = "1",

}

TY - JOUR

T1 - Antisense oligonucleotides targeting angiotensinogen

T2 - Insights from animal studies

AU - Wu, Chia Hua

AU - Wang, Ya

AU - Ma, Murong

AU - Mullick, Adam E.

AU - Crooke, Rosanne M.

AU - Graham, Mark J.

AU - Daugherty, Alan

AU - Lu, Hong S.

N1 - Funding Information: The authors’ research work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health [grant numbers R01HL139748, R01HL133723] and the National Natural Science Foundation of China [grant numbers 81320108003, 31371498 (to Y.W.)]; Employees of Ionis Pharmaceuticals, Inc. [to A.E.M. and R.M.C.]; M.J.G. was an employee of Ionis Pharmaceuticals, Inc. The content in this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2019 The Author(s).

PY - 2019/1/11

Y1 - 2019/1/11

N2 - Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.

AB - Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving therapeutic approach. The scope of the research findings not only opens doors for potentially new therapeutics of hypertension and many other diseases, but also provides insights into understanding critical physiological and pathophysiological roles mediated by AGT.

UR - http://www.scopus.com/inward/record.url?scp=85059807934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059807934&partnerID=8YFLogxK

U2 - 10.1042/BSR20180201

DO - 10.1042/BSR20180201

M3 - Review article

C2 - 30530571

AN - SCOPUS:85059807934

VL - 39

IS - 1

M1 - BSR20180201

ER -

Antisense oligonucleotides targeting angiotensinogen: Insights from animal studies

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this